Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Scilex Holding Co | Executive Vice President, Chief Business Officer and Chief Financial Officer | Nonstatutory Stock Option (right to buy) | 350K | Jan 17, 2023 | Direct | ||
Sorrento Therapeutics, Inc. | EVP & Chief Financial Officer | Stock Option (right to buy) | 350K | May 18, 2022 | Direct | ||
DELCATH SYSTEMS, INC. | Director | Stock Option (right to buy) | 22.5K | May 23, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
DCTH | DELCATH SYSTEMS, INC. | May 23, 2024 | 1 | $0 | 4 | May 28, 2024 | Director |
DCTH | DELCATH SYSTEMS, INC. | Jun 12, 2023 | 1 | $0 | 4 | Jun 21, 2023 | Director |
SCLX | Scilex Holding Co | Jan 17, 2023 | 1 | $0 | 4 | Jan 17, 2023 | Executive Vice President, Chief Business Officer and Chief Financial Officer |
SCLX | Vickers Vantage Corp. I | Nov 10, 2022 | 0 | $0 | 3 | Nov 15, 2022 | Officer |
SRNEQ | Sorrento Therapeutics, Inc. | May 18, 2022 | 1 | $0 | 4 | May 20, 2022 | EVP & Chief Financial Officer |
DCTH | DELCATH SYSTEMS, INC. | May 4, 2022 | 1 | $0 | 4 | May 6, 2022 | Director |
SRNEQ | Sorrento Therapeutics, Inc. | Nov 18, 2021 | 1 | $0 | 4 | Nov 18, 2021 | Director |
SRNEQ | Sorrento Therapeutics, Inc. | Nov 15, 2021 | 0 | $0 | 3 | Nov 18, 2021 | Director |
DCTH | DELCATH SYSTEMS, INC. | Aug 5, 2021 | 1 | $0 | 4 | Aug 9, 2021 | Director |